Central retinal vein occlusion as first manifestation of relapse in acute lymphoblastic leukemia.

Rev Bras Hematol Hemoter

Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil.

Published: June 2015

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459482PMC
http://dx.doi.org/10.1016/j.bjhh.2015.03.008DOI Listing

Publication Analysis

Top Keywords

central retinal
4
retinal vein
4
vein occlusion
4
occlusion manifestation
4
manifestation relapse
4
relapse acute
4
acute lymphoblastic
4
lymphoblastic leukemia
4
central
1
vein
1

Similar Publications

Purpose: To identify optical coherence tomography (OCT)-based imaging biomarkers that can localize focal leakage points without fluorescein angiography in central serous chorioretinopathy (CSC).

Methods: This retrospective case-control study analyzed 119 consecutive patients (123 eyes) with CSC between April 2018 and February 2024, comprising 66 eyes with focal-leakage type and 57 eyes with diffuse-leakage type. We assessed leakage sites using OCT, and the proportions of OCT findings were compared between focal- and diffuse-leakage types.

View Article and Find Full Text PDF

Purpose: To characterize retinal vessel whitening (RVW) in Retinitis Pigmentosa (RP).

Methods: Single-center cross-sectional study. Review of clinical notes of clinically confirmed RP patients was performed followed by grading ultra-widefield imaging.

View Article and Find Full Text PDF

Purpose: To present a novel bended-needle drainage system in vitreous cavity lavage (VCL) for postoperative vitreous cavity hemorrhage (POVCH).

Methods: This retrospective case series include all patients with POVCH who received VCL with the bended-needle drainage system at ophthalmology department of Peking Union Medical College Hospital from January 2022 to May 2024. Patients adopted a supine position that allows preparation and draping.

View Article and Find Full Text PDF

Background And Objective: To assess the efficacy of intravitreal aflibercept 8 mg in treating neovascular age-related macular degeneration (nAMD) in patients previously treated with faricimab.

Patients And Methods: A retrospective study was conducted on nAMD patients with suboptimal response to faricimab injections who were switched to intravitreal aflibercept 8 mg. Visual acuity (VA) and optical coherence tomography features were evaluated.

View Article and Find Full Text PDF

Background: Stargardt disease type 1 (STGD1) is a progressive retinal disorder caused by bi-allelic variants in the ABCA4 gene. A recurrent variant at the exon-intron junction of exon 6, c.768G>T, causes a 35-nt elongation of exon 6 that leads to premature termination of protein synthesis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!